In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Ulrich Laufs
Speaker
Ulrich Laufs

Leipzig University Hospital, Leipzig (Germany)

Speciality : Interventional Cardiology

29 presentations from this speaker

Aspirin in patients with diabetes: primary prevention, secondary prevention or both?

Congress : ESC Congress 2019

  • Session : Translating data to practice: aspirin in high-risk patient subgroups
  • Speaker : U Laufs (Leipzig,DE), F Andreotti (Rome,IT)
  • Sponsored by Bayer AG

Challenges to achieve treatment goals with current therapies

Congress : ESC Congress 2019

  • Session : Beyond statins - Evolving concepts for the management of dyslipidaemia
  • Speaker : U Laufs (Leipzig,DE)
  • Daiichi Sankyo Europe Gmbh

Emerging treatments for high cardiovascular risk patients.

Congress : ESC Congress 2019

  • Session : Targeting dyslipidemia in the Asia Pacific Region
  • Speaker : U Laufs (Leipzig,DE)
  • Sponsored by Sahmri

Looking beyond patient age: the role of aspirin in cardiovascular risk management

Congress : ESC Congress 2019

  • Session : Translating data to practice: aspirin in high-risk patient subgroups
  • Speaker : F Andreotti (Rome,IT), U Laufs (Leipzig,DE)
  • Sponsored by Bayer AG

State of the Art - The symphony of lipids in 2019

Congress : ESC Congress 2019

  • Session : Lipid modification for the 21st century
  • Speaker : U Laufs (Leipzig,DE)

Cholesterol targets in secondary and primary prevention .

Congress : ESC Congress 2018

  • Session : Expert Advice - Cholesterol-lowering treatment made easy
  • Speaker : U Laufs (Leipzig,DE)

Discussant review - ARRIVE.

Congress : ESC Congress 2018

  • Session : Hot Line Session 1
  • Speaker : U Laufs (Leipzig,DE)

Discussion and summary - LDL-c: done deal, next epigenetics? .

Congress : ESC Congress 2018

  • Session : LDL-c: done deal, next epigenetics? (EBAC Accredited)
  • Speaker : U Laufs (Leipzig,DE)
  • Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Resverlogix

Introduction - LDL-c: done deal, next epigenetics?

Congress : ESC Congress 2018

  • Session : LDL-c: done deal, next epigenetics? (EBAC Accredited)
  • Speaker : U Laufs (Leipzig,DE)
  • Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Resverlogix

Is it time to sing the requiem for HDL cholesterol?

Congress : ESC Congress 2018

  • Session : Lipid-lowering therapy beyond LDL Cholesterol
  • Speaker : U Laufs (Leipzig,DE)

Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!

Congress : ESC Congress 2018

  • Session : Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!
  • Speaker : U Laufs (Leipzig,DE), GM De Ferrari (Pavia,IT), RP Giugliano (Boston,US)
  • Sponsored by Amgen Europe GmbH

Panel discussion and close - Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!

Congress : ESC Congress 2018

  • Session : Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!
  • Speaker : U Laufs (Leipzig,DE), GM De Ferrari (Pavia,IT), N Sattar (Glasgow,GB), RP Giugliano (Boston,US)
  • Sponsored by Amgen Europe GmbH

PCSK9: Cardiovascular role beyond the liver.

Congress : ESC Congress 2018

  • Session : New insights into lipid biology and cardiovascular disease
  • Speaker : U Laufs (Leipzig,DE)

The criticality of elevated LDL-C

Congress : ESC Congress 2018

  • Session : Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!
  • Speaker : U Laufs (Leipzig,DE)
  • Sponsored by Amgen Europe GmbH

Treating cardiovascular patients at risk: cases in action

Congress : ESC Congress 2018

  • Session : Optimising cardiovascular outcomes with PCSK9 inhibitors: start now before a potential next MI or stroke!
  • Speaker : GM De Ferrari (Pavia,IT), U Laufs (Leipzig,DE), N Sattar (Glasgow,GB)
  • Sponsored by Amgen Europe GmbH

How to approach the young patient with multiple risk factors.

Congress : ESC Congress 2017

  • Session : An update on cardiovascular prevention
  • Speaker : U Laufs (Leipzig,DE)

Familial hypercholesterolaemia, underdiagnosed and undertreated condition

Congress : ESC Congress 2016

  • Session : What has changed since the previous Guidelines in lipidology?
  • Speaker : U Laufs (Leipzig,DE)

PCSK9i: translating data into daily practice.

Congress : ESC Congress 2016

  • Session : PCSK9i: translating data into daily practice
  • Speaker : E Stroes (Amsterdam,NL), U Laufs (Leipzig,DE)
  • Sponsored by Amgen Cardiovascular

PCSK9i: translating the data.

Congress : ESC Congress 2016

  • Session : PCSK9i: translating data into daily practice.
  • Speaker : U Laufs (Leipzig,DE)
  • Sponsored by Amgen Cardiovascular

Closing - Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion.

Congress : ESC Congress 2015

  • Session : Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion
  • Speaker : C Cannon (Boston,US), U Laufs (Leipzig,DE)
  • Sponsored by MSD

Opening by the chairs - Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion.

Congress : ESC Congress 2015

  • Session : Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion
  • Speaker : C Cannon (Boston,US), U Laufs (Leipzig,DE)
  • Sponsored by MSD

Panel discussion & Q&A - Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion.

Congress : ESC Congress 2015

  • Session : Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion
  • Speaker : C Cannon (Boston,US), U Laufs (Leipzig,DE), BA Ference (Cambridge,GB), AK Gitt (Ludwigshafen,DE), P Toth (Sterling,US)
  • Sponsored by MSD

Controversial recommendations on LDL-lowering treatment - LDL-C goals/individual therapy.

Congress : ESC Congress 2014

  • Session : Current controversies in prevention
  • Speaker : U Laufs (Leipzig,DE)

Effects of PCSK9 inhibitors in addition to regulation of the low-density lipoprotein-receptor?

Congress : ESC Congress 2014

  • Session : Critical review of innovations in lipid-lowering therapy
  • Speaker : U Laufs (Leipzig,DE)

Patient with controlled LDL-C but high Lp(a).

Congress : ESC Congress 2014

  • Session : Controversial cases in lipid management
  • Speaker : U Laufs (Leipzig,DE)

Inflammation: LpPLA2 inhibitors and peroxisome proliferation-activated receptor alpha/gamma agonists.

Congress : ESC Congress 2013

  • Session : Critical review of non-statin treatments for dyslipidaemia
  • Speaker : U Laufs (Leipzig,DE)

Pro: rebuttal 'we are currently static with statins'.

Congress : ESC Congress 2013

  • Session : 'We are currently static with statins' Is there a real need to move beyond current standards of care?
  • Speaker : U Laufs (Leipzig,DE)
  • Sponsored by AMGEN

Pro: 'we are currently static with statins'.

Congress : ESC Congress 2013

  • Session : 'We are currently static with statins' Is there a real need to move beyond current standards of care?
  • Speaker : U Laufs (Leipzig,DE)
  • Sponsored by AMGEN

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are